Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
30-Dec-2025 | 827.65 | 833.9 | 820.05 | 823.6 | 5,730 | 9,40,80,134.1 | 45,428 |
31-Dec-2025 | 821.55 | 828.6 | 812 | 822.2 | 5,655 | 10,11,85,236.85 | 59,806 |
01-Jan-2026 | 825 | 828.45 | 818.15 | 826.45 | 3,222 | 5,98,40,001.4 | 37,233 |
02-Jan-2026 | 823.05 | 869 | 823.05 | 865.3 | 22,438 | 49,98,27,159.7 | 2,49,162 |
05-Jan-2026 | 863.5 | 873.7 | 842.65 | 847.8 | 13,183 | 32,07,23,875.8 | 1,91,788 |
06-Jan-2026 | 847.8 | 866 | 842 | 844.95 | 10,257 | 17,79,81,768.85 | 86,360 |
07-Jan-2026 | 845 | 876.5 | 845 | 864.7 | 12,285 | 24,02,57,227.9 | 1,02,032 |
08-Jan-2026 | 862.1 | 862.1 | 815 | 821.4 | 11,851 | 23,34,74,201.1 | 1,42,727 |
09-Jan-2026 | 815.95 | 835.2 | 803.6 | 811.4 | 10,650 | 19,07,63,152.15 | 89,927 |
12-Jan-2026 | 817.2 | 832.55 | 787.7 | 813.7 | 12,753 | 21,66,17,744.05 | 1,05,834 |
13-Jan-2026 | 823 | 823 | 798 | 812.95 | 4,786 | 8,85,00,864.1 | 39,858 |
14-Jan-2026 | 812.95 | 820.95 | 797.6 | 803.15 | 4,238 | 9,54,85,451.05 | 68,081 |
16-Jan-2026 | 803.15 | 814.4 | 787 | 790.05 | 6,994 | 14,93,50,622.45 | 1,01,562 |
19-Jan-2026 | 790 | 812.8 | 757.65 | 805.95 | 8,909 | 19,55,20,247.7 | 1,07,555 |
20-Jan-2026 | 805.95 | 821 | 752.4 | 784.55 | 39,973 | 98,23,57,781.65 | 2,59,369 |
21-Jan-2026 | 799.9 | 840 | 773 | 835 | 34,188 | 89,67,73,777.85 | 2,87,007 |
22-Jan-2026 | 846.95 | 851.95 | 825.6 | 838.15 | 11,154 | 23,68,51,748.1 | 1,04,620 |
23-Jan-2026 | 836 | 836 | 794.85 | 802 | 7,513 | 16,22,81,897.75 | 1,13,251 |
27-Jan-2026 | 805 | 805.05 | 779.75 | 791.1 | 6,929 | 13,56,03,445.85 | 56,183 |
The acquisition will be carried out in two tranches and has received approval from the management committee of the company’s board.
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
